Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc. (NBIX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Neurocrine is a neuroscience-focused biopharmaceutical company commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. Key commercial products include INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and CRENESSITY (crinecerfont), launched in December 2024 for classic congenital adrenal hyperplasia (CAH). The company maintains a robust pipeline in psychiatry (osavampator, direclidine), neurology, and endocrinology.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenues | $2,860.5 | $2,355.3 | $1,887.1 |
| Net Product Sales | $2,833.9 | $2,330.6 | $1,860.6 |
| Operating Income | $619.1 | $570.5 | $250.9 |
| Net Income | $478.6 | $341.3 | $249.7 |
| Diluted EPS | $4.67 | $3.29 | $2.47 |
| Operating Cash Flow | $782.7 | $595.4 | $389.9 |
| Cash & Marketable Securities | $2,543.4 | $1,815.6 | N/A |
| Working Capital | $1,779.3 | $1,217.0 | N/A |
Product Sales Breakdown (2025):
- INGREZZA: $2,513.7 million
- CRENESSITY: $301.2 million (first full year of launch)
- Other: $19.0 million
Expense Highlights (2025):
- Research and Development: $1,015.7 million (35.5% of revenue)
- Selling, General, and Administrative: $1,156.2 million (40.4% of revenue)
- Cost of Revenues: $52.1 million (1.8% of revenue)
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 21.6% to $2.86 billion, driven by the full-year contribution of CRENESSITY ($301.2 million) and continued growth in INGREZZA sales ($2.51 billion), which reached record prescription volumes.
- Profitability: Net income increased 40.2% to $478.6 million, supported by revenue growth and the absence of the $138.4 million charge associated with convertible senior notes that occurred in 2024.
- R&D Investment: R&D expenses increased 38.9% to $1.02 billion, reflecting increased investments in Phase 3 programs for osavampator (MDD) and direclidine (schizophrenia), and expanded discovery efforts in biologics and gene therapy.
- SG&A Increase: SG&A expenses rose 14.8% to $1.16 billion due to commercial expansion for CRENESSITY and INGREZZA, partially offset by reduced impairment charges on legacy facilities compared to 2024.
- Share Repurchases: The company repurchased 1.5 million shares for $167.7 million under the 2025 program and settled a $300 million accelerated repurchase program from 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy:
- Commercial Expansion: Sales teams for INGREZZA and CRENESSITY are expanding, with completion expected by Q1 2026 to maximize market penetration.
- Pipeline Milestones: Phase 3 programs initiated for osavampator (MDD) and direclidine (schizophrenia) with initial topline data expected in 2027. Phase 1 studies initiated for several new candidates including NBIP-01435 (CAH) and NBI-921355 (epilepsy).
- Capital Allocation: $332.3 million remains available under the $500 million 2025 share repurchase program.
Risks and Contingencies:
- Regulatory Investigation: In August 2025, the company received a civil investigative demand from the U.S. Department of Justice (DOJ) regarding the sales and marketing of INGREZZA. The company is cooperating, but the outcome is uncertain.
- Healthcare Reform: The Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA) introduce pricing pressures. INGREZZA currently qualifies for the "small biotech exception" to Medicare price negotiation until 2027, but future qualification is not guaranteed.
- Competitive Landscape: INGREZZA faces competition from AUSTEDO (deutetrabenazine), which was selected for Medicare price negotiation in 2025, potentially increasing competitive pressure.
- Supply Chain: Reliance on third-party manufacturers for all products creates supply risk, exacerbated by potential tariffs on imported pharmaceutical ingredients.
Unusual Items:
- Asset Sale: On January 21, 2026 (subsequent to year-end), the company completed the sale of Neurocrine Group Limited for $65.0 million, expecting to recognize a gain in Q1 2026.
- Failed Trials: Phase 3 studies for valbenazine in schizophrenia and dyskinesia due to cerebral palsy, and a Phase 2 study for NBI-1070770 in MDD, did not meet primary endpoints in 2025.
Investor Verification Checklist
- DOJ Investigation Status: Monitor updates regarding the DOJ civil investigative demand into INGREZZA marketing practices.
- CRENESSITY Adoption: Verify commercial uptake and reimbursement rates for CRENESSITY in its first full year post-launch.
- Medicare Pricing Exemptions: Confirm continued eligibility for the "small biotech exception" to Medicare drug price negotiation for INGREZZA beyond 2027.
- Pipeline Progress: Track enrollment and topline data timelines for Phase 3 programs (osavampator, direclidine) scheduled for 2027.
- Share Repurchase Activity: Monitor execution of the remaining $332.3 million authorization under the 2025 repurchase program.
- Neurocrine Group Sale: Confirm the final gain recognition and cash proceeds from the January 2026 sale of Neurocrine Group Limited.